Gencaro Approval Status
FDA Approved: No
Brand name: Gencaro
Generic name: bucindolol
Company: ARCA biopharma, Inc.
Treatment for: Heart Failure
Gencaro (bucindolol) is an investigational and pharmacologically unique beta-blocker and mild vasodilator in development for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction, HFREF).
Development Status and FDA Approval Process for Gencaro
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.